Research News

Androgen deprivation therapy may be linked to increased risk of dementia

BMJ 2016; 355 doi: http://dx.doi.org/10.1136/bmj.i5572 (Published 17 October 2016) Cite this as: BMJ 2016;355:i5572
  1. Jacqui Wise
  1. London

Androgen deprivation therapy (ADT), a common treatment for prostate cancer, may be associated with an increased risk of dementia, new research in JAMA Oncology has found.1

Androgen deprivation therapy is used to reduce levels of androgens as they stimulate prostate cancer cells to grow. The approach has shown survival benefit in some patients but has also been associated with adverse health effects—for example, growing evidence supports a link between ADT and neurocognitive dysfunction.

The researchers …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe